company background image
HARP

Harpoon Therapeutics NasdaqGS:HARP Stock Report

Last Price

US$1.02

Market Cap

US$33.9m

7D

-13.6%

1Y

-78.3%

Updated

05 Feb, 2023

Data

Company Financials +

Harpoon Therapeutics, Inc.

NasdaqGS:HARP Stock Report

Mkt Cap: US$33.9m

HARP Stock Overview

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States.

HARP fundamental analysis
Snowflake Score
Valuation2/6
Future Growth1/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Harpoon Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Harpoon Therapeutics
Historical stock prices
Current Share PriceUS$1.02
52 Week HighUS$6.20
52 Week LowUS$0.59
Beta1.35
1 Month Change36.00%
3 Month Change27.48%
1 Year Change-78.25%
3 Year Change-93.15%
5 Year Changen/a
Change since IPO-92.44%

Recent News & Updates

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Recent updates

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

We're Not Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn

May 07
We're Not Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn

News Flash: Analysts Just Made A Sizeable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Mar 16
News Flash: Analysts Just Made A Sizeable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Harpoon Therapeutics (NASDAQ:HARP) Shareholders Booked A 37% Gain In The Last Year

Mar 10
Harpoon Therapeutics (NASDAQ:HARP) Shareholders Booked A 37% Gain In The Last Year

Could The Harpoon Therapeutics, Inc. (NASDAQ:HARP) Ownership Structure Tell Us Something Useful?

Feb 03
Could The Harpoon Therapeutics, Inc. (NASDAQ:HARP) Ownership Structure Tell Us Something Useful?

Harpoon Therapeutics' HPN217 an orphan drug in U.S. for multiple myeloma

Jan 13

Harpoon Therapeutics -2.6%, proposes public offering

Jan 06

Harpoon Therapeutics: Potential For Explosive Growth

Jan 03

Have Insiders Been Buying Harpoon Therapeutics, Inc. (NASDAQ:HARP) Shares This Year?

Dec 30
Have Insiders Been Buying Harpoon Therapeutics, Inc. (NASDAQ:HARP) Shares This Year?

Harpoon Therapeutics reports partial response from HPN424 early-stage study in prostate cancer

Dec 08

Shareholder Returns

HARPUS BiotechsUS Market
7D-13.6%-0.8%1.7%
1Y-78.3%4.4%-9.6%

Return vs Industry: HARP underperformed the US Biotechs industry which returned 4.4% over the past year.

Return vs Market: HARP underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is HARP's price volatile compared to industry and market?
HARP volatility
HARP Average Weekly Movement22.6%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: HARP is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 23% a week.

Volatility Over Time: HARP's weekly volatility has increased from 17% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201586Julie Eastlandhttps://www.harpoontx.com

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.

Harpoon Therapeutics, Inc. Fundamentals Summary

How do Harpoon Therapeutics's earnings and revenue compare to its market cap?
HARP fundamental statistics
Market CapUS$33.89m
Earnings (TTM)-US$70.86m
Revenue (TTM)US$32.15m

1.1x

P/S Ratio

-0.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HARP income statement (TTM)
RevenueUS$32.15m
Cost of RevenueUS$72.37m
Gross Profit-US$40.22m
Other ExpensesUS$30.65m
Earnings-US$70.86m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.13
Gross Margin-125.09%
Net Profit Margin-220.41%
Debt/Equity Ratio0%

How did HARP perform over the long term?

See historical performance and comparison